Establishment and Validation of a Stable, Cell-Based Diabetic Wound Bioassay

稳定的、基于细胞的糖尿病伤口生物测定的建立和验证

• 批准号: G0800696/1
• 负责人: Phil Stephens
• 金额: $ 31.04万
• 依托单位: CARDIFF UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0800696%2F1
• 关键词: Establishment; Validation; Stable; Cell; Based

Delayed skin wound healing and foot ulcers affect up to 15% of diabetic patients. This impaired skin wound healing has been attributed to changes in the cells of the skin which may be altered by the disease. Currently, no suitable diabetic wound model exists and so inadequate animal models and human testing are often undertaken. This project will develop a simple, reproducible, laboratory-based diabetic wound model system to permit rapid, low cost testing of materials, reagents and drugs and importantly reduce unnecessary animal experimentation. We have already isolated normal and diseased (diabetic) cells from patients, altered them so that they grow forever and identified diabetic wound disease marker genes. This new project will use these disease marker genes to develop a cell-based reporter system, enabling automated testing and pre-screening of reagents which may ameliorate the diabetic wound disease state. It is our aim to develop this bioassay commercially, producing a high-throughput screening system which will reduce the amount of unnecessary animal studies undertaken with respect to wound products/materials testing.

皮肤伤口愈合延迟和足部溃疡影响高达15%的糖尿病患者。这种受损的皮肤伤口愈合归因于皮肤细胞的变化，这些变化可能被疾病改变。目前，不存在合适的糖尿病伤口模型，因此经常进行不充分的动物模型和人体试验。该项目将开发一种简单、可重复、基于实验室的糖尿病伤口模型系统，以快速、低成本地测试材料、试剂和药物，并减少不必要的动物实验。我们已经从患者身上分离出正常和患病（糖尿病）细胞，改变它们，使它们永远生长，并确定了糖尿病伤口疾病标记基因。这个新项目将使用这些疾病标记基因来开发基于细胞的报告系统，从而实现自动化测试和预筛选试剂，这可能会改善糖尿病伤口疾病状态。我们的目标是商业化地开发这种生物测定，产生高通量筛选系统，这将减少在伤口产品/材料测试方面进行的不必要的动物研究的量。